Introduction
============

Granular cell tumors (GCTs) are rare and were first described by Abrikossof in 1926 ([@b1-ol-0-0-8811]). These tumors are generally benign and only 1--2% of cases were reported malignant ([@b2-ol-0-0-8811],[@b3-ol-0-0-8811]). The malignant form has a reported 3-year mortality rate of 60% ([@b4-ol-0-0-8811]). GCTs have been reported in soft tissue, including skin, tongue, subcutaneous tissue and skeletal muscle. Multiple lesions in the skin occur in \~16% of all cases ([@b2-ol-0-0-8811]); however, gastrointestinal involvement, particularly the colon, is extremely rare ([@b5-ol-0-0-8811],[@b6-ol-0-0-8811]). Colonic GCTs are often asymptomatic and may be detected incidentally during colonoscopy screening or through examination performed for non-specific gastrointestinal symptoms.

To date, the majority of what is known regarding GCTs is limited to case reports. For example, Hong and Lim ([@b7-ol-0-0-8811]) reported a case of GCT in the cecum, which was removed via laparoscopic approach. Cha *et al* ([@b8-ol-0-0-8811]) described a case of GCT in the descending colon, which was treated by endoscopic mucosal resection. Due to its rarity, arguments remain regarding diagnosis and treatment. The development of endoscopic technology has provided a new perspective on diagnosis and treatment for colonic GCTs. The present study describes 11 cases of colonic GCTs, including clinical manifestations, endoscopic and endoscopic ultrasonography (EUS) features, pathology, immunohistochemistry, treatment, and morbidity. Special attention is given to the safety and feasibility of endoscopic treatment.

Materials and methods
=====================

### Preoperative evaluation

Patients who received a diagnosis of GCT between March 2010 and April 2015 at Gastrointestinal Endoscopy Center of Fujian Provincial Hospital (Fuzhou, China) were included in the present study. The following data were registered: Patient demographics, clinical manifestations, endoscopic characteristics, EUS appearance, pathology, immunohistochemistry, treatment and associated morbidity.

All patients underwent blood tests, including hematic biometry and clotting times, prior to the endoscopic procedure. Colonoscopy, EUS, chest X-ray and abdominal computerized tomography were performed to determine the feasibility of endoscopic treatment. All patients provided signed informed consent to accept the endoscopic procedure after receiving information regarding the treatment, risks, and benefits. Written informed consent was received from all patients for publication of the data in the present study.

Under EUS, the following were recorded: Tumor location, color, maximum diameter, superficial appearance and the involved layer within the colonic wall. Lesions ≤2 cm in maximum diameter and limited to the mucosa or submucosal layer were selected for endoscopic submucosal dissection (ESD). Lesions in the submucosal layer or \>2 cm in diameter were selected for endoscopic submucosal excavation (ESE).

### Endoscopic resection of GCTs

A single-accessory-channel endoscope with a water-jet (PCF-Q260AZI; Olympus Corporation, Tokyo, Japan) was used. A short transparent cap (ND-201-11802; Olympus Corporation) was used to ensure a clear endoscopic view and apply tension to the connective tissue during the dissection. CO~2~ insufflation was employed to alleviate abdominal discomfort during the ESD procedure. Several types of electrosurgical knives were applied depending on necessity, including the dual, hook or insulated-tip (KD-650Q, KD-260R and KD611, respectively; Olympus Corporation). The HybridKnife system (ERBE, Tübingen, Germany) was used as the electrosurgical generator. Injection needles (NM4L1), argon plasma coagulation unit (APC300, ERBE), snares, hot biopsy forceps and clips (SD230U20, FD410LR and HX610-135, respectively; Olympus Corporation) were used during the operation.

The standard ESD procedure has been previously described by numerous authors ([@b9-ol-0-0-8811]) ([Fig. 1](#f1-ol-0-0-8811){ref-type="fig"}). Herein, the specific protocol used in the submucosal injection step was highlighted. Due to the duration required for ESD, a solution consisting of 10% sodium hyaluronate, 5% lidocaine and 0.5% indicarmine dye was injected into the submucosa around the lesion, helping to lift the mucosa, and reduce the risk of perforation.

One patient with a tumor 3 cm in diameter received ESE treatment ([Fig. 2](#f2-ol-0-0-8811){ref-type="fig"}), as follows. To lift the tumor, a submucosal injection of several milliliters of the mixed solution aforementioned around the lesion was performed using a 23-gauge disposable needle. A mucosectomy was performed in which the superficial mucosa was incised using a dual knife. The tumor was carefully resected from the connecting tissue using a proper knife (dual or insulation-tipped) to achieve an *en bloc* resection. For closure, exposed vessels on the surface or at the edge of the wound were coagulated with hot biopsy forceps to prevent delayed bleeding and metallic clips were used to close the wound. The duration between marking foci and complete resection of the tumor was noted.

### Pathological diagnosis

All resected specimens were fixed in 10% formalin solution for 6--8 h at room temperature. Thereafter, they were embedded in paraffin and cut into 5-µm sections. Hematoxylin-eosin staining was performed in accordance with a previous study ([@b10-ol-0-0-8811]). Immunohistochemical examination was conducted for suspected GCTs. For immunohistochemical analysis, paraffin-embedded sections were deparaffinized in xylene for 5 min and hydrated in graded ethanol (100% ethanol for 5 min, 95% ethanol for 3 min, 85% ethanol for 3 min, 80% ethanol for 3 min and 75% ethanol for 3 min, respectively) to prior to immunostaining. Sections were soaked in 10 mM citrate buffer (pH 6.0) and treated at 125°C for 5 min using a pressure boiler (Decloaking chamber, Biocare Medical LCC, Pacheco, CA, USA) to perform heat-induced antigen retrieval. Sections were left in the pressure boiler to cool following complete boiling. Specimens were then immersed in 5% bovine serum albumin solution at 37°C for 40 mins to block non-specific interaction sites. Sections were incubated with rabbit anti-human S100 (1:6,000; cat. no. PL032696R; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) overnight at 4°C, and then with goat anti-rabbit biotin-conjugated secondary antibody (1:2,000; cat. no. A21 220; Abcam, Cambridge, UK) at 37°C for 30 min, and subsequently washed three times with PBS. Staining was performed at room temperature for 30 min, using the avidin-biotin-peroxidase complex method (Vectastain; Vector Laboratories, Inc., Burlingame, CA, USA). Sections were counterstained with hematoxylin-eosin for 1 min at room temperature. Following staining, sections were dehydrated, mounted and viewed via light microscopy (original magnification, ×200).

### Follow-up protocol

Patients with lesions \<1 cm and benign tumors determined by pathology were followed-up annually. Patients with tumors \>1 cm or considered histopathologically atypical were supervised every 6 months for the first 2 years and annually thereafter. All patients were monitored for recurrence using thoracic computed tomography scans, endoscopy and EUS.

Results
=======

Eleven patients (7 males and 4 females) with a mean age of 49.91 years (range, 40--67 years) were diagnosed with GCT ([Table I](#tI-ol-0-0-8811){ref-type="table"}). Eight patients were asymptomatic and the tumors were identified via colonoscopy screening. Three patients were referred to the Gastrointestinal Endoscopy Center of Fujian Provincial Hospital complaining of hematochezia (1 patient) and abdominal pain (2 patients). Eight lesions were located in the ascending colon and 3 in the cecum; all of them were solitary.

White-light colonoscopy revealed a yellowish or white, solid and well-circumscribed tumor covered by smooth superficial mucosa ([Fig. 3A and B](#f3-ol-0-0-8811){ref-type="fig"}). On EUS, these colonic GCTs appeared as homogenous originating from the muscularis mucosa (3 cases; [Fig. 3C](#f3-ol-0-0-8811){ref-type="fig"}) or a granular-type heterogeneous hypoechoic solid tumor arising from the submucosal layer (8 cases; [Fig. 3D](#f3-ol-0-0-8811){ref-type="fig"}). The tumors were well circumscribed with no compression of neighboring organs and no lymph node was affected. The tumor diameters ranged between 0.3 and 3.0 cm, with a mean diameter of 1.1 cm.

All patients underwent endoscopic resection, based on the tumor characteristics. Ten patients with tumor size ≤2 cm and located within the muscularis mucosa or submucosal layer underwent standardized ESD to insure complete resection of the tumor. Another patient with a GCT 3 cm in diameter and originating from the submucosal layer accepted ESE for treatment. Tumors were removed *en bloc* without complications. The mean operative duration was 38 min (range, 31 to 50 min).

Pathological diagnosis of the tumor was performed on all patients. No GCT tissue was detected at the bottom or on the edge of the specimens, indicating complete resection. Histologically, all GCT lesions showed a well-circumscribed growth pattern within the submucosal layer. The gross specimen was a solitary and peanut-like nodule with a yellowish cross-section. Microscopically, the neoplastic cells were characterized by small, uniform nuclei surrounded by abundant granular eosinophilic cytoplasm ([Fig. 4A](#f4-ol-0-0-8811){ref-type="fig"}). Typical histopathological features confirmed the diagnosis of GCT. Further immunohistochemical analysis revealed positive staining for S-100 in the nucleus and cytoplasm for all cases ([Fig. 4B](#f4-ol-0-0-8811){ref-type="fig"}). None of the lesions met the criteria for malignant or atypical GCT ([@b3-ol-0-0-8811]). There, all were determined to be histologically benign.

All patients completed follow-ups of 11 months to 5 years. None of the patients complained of any discomfort or experienced massive weight loss during their follow-up period. Colonoscopy and EUS were performed in all patients and none exhibited recurrence or metastasis.

Discussion
==========

GCTs are a rare type of soft tissue tumors that may be detected anywhere throughout the body, most commonly in the oral cavity, skin, skeletal muscle and subcutaneous tissue, but also in the nervous system, respiratory tract, and female genital organs ([@b11-ol-0-0-8811],[@b12-ol-0-0-8811]). GCTs are relatively uncommon in the gastrointestinal track, accounting for 5--11% of all GCTs ([@b5-ol-0-0-8811],[@b6-ol-0-0-8811],[@b13-ol-0-0-8811]). To date, \~130 cases of colonic GCTs have been reported in the English literature ([@b14-ol-0-0-8811]). Among the relatively rare locations, the esophagus is involved most frequently, then the duodenum, anus and stomach. Least common is the colon and rectum, where primarily the ascending colon, cecum, appendix, and rectum are affected ([@b8-ol-0-0-8811]). In the present report, the tumors were identified in the ascending colon (8 cases) and cecum (3 cases).

The sex and age distribution of GCT remains controversial in the literature, partially due to cases that were insufficiently described. Singhi *et al* ([@b14-ol-0-0-8811]) reported an equal sex distribution, with ages ranging between 31 and 60 years. An *et al* ([@b15-ol-0-0-8811]) observed a male predominance, with a wider age distribution between 21 and 75 years. In the present study, the male-to-female ratio was 7:4, with ages ranging between 40 and 67 years.

Colonic GCTs tend to be asymptomatic and usually follow a benign course. The lesions are usually identified during colonoscopy screening or examinations performed for other reasons. Patients who had discomfort may exhibit larger lesions. However, this association is not strong regarding colonic GCTs. Common symptoms are non-specific, including abdominal discomfort, hematochezia and changes in bowel habits. In the present study, 8 patients were asymptomatic and 3 complained of hematochezia (1 patient) and abdominal pain (2 patients). An association between the symptoms of the 3 patients and colonic GCT of the mucosal layer is unlikely. Multiple GCTs in children may be indicative of neurofibromatosis ([@b16-ol-0-0-8811]), Noonan syndrome ([@b17-ol-0-0-8811]), growth retardation or Hodgkin\'s disease in remission ([@b18-ol-0-0-8811]). However, the statistical power is not sufficient due to the scarcity of cases.

In the present cases, the white-light colonoscopy showed a yellowish or white, well-circumscribed tumor covered by normal mucosa. A few cases may show rough mucosa or ulceration on the top of the lesion, due to an inflammatory reaction to the mucosa. The lesion is usually solitary and \<2 cm in diameter. However, multiple lesions within the gastrointestinal track or involved extra-gastrointestinal sites have also been reported in 10--20% of all GCTs ([@b19-ol-0-0-8811]), and the largest tumor has been 4 cm in diameter ([@b20-ol-0-0-8811]).

EUS is essential to determine the invasion depth and nature of GCTs. Typical colonic GCTs are characterized by homogeneous or mild heterogeneous hypoechoic nodules with a growth pattern within the mucosa or submucosa. In the current study, 8 tumors were detected in the submucosal layer with a hypoechoic but granular-type heterogeneous ultrasonography image. This particular feature may facilitate the diagnosis of colonic GCTs. However, colonoscopy examination or EUS features are not reliable enough to confirm a diagnosis of GCT.

The final diagnosis of GCT is based on histopathology findings. The typical pathological characteristics of GCT and positive staining for S-100 protein support an accurate diagnosis; the key is to get precise GCT tissue. GCTs located at the mucosa may benefit from biopsy. However, for those restricted to the submucosal area an endoscopic forceps biopsy is not recommended, because it may not pick up the actual lesion, but destroy the tumor integrity with subsequent bleeding.

EUS-guided fine needle aspiration is valuable for pathological determination. However, the extracted biopsy tissue is of limited size and the malignant location may be missed, leading to a false diagnosis. Complete resection is the optimal strategy to obtain specimens of submucosal tumors. None of the cases in the present report underwent biopsy, considering that all lesions were submucosal tumors.

GCTs are generally considered benign with malignant potential (1--2%) ([@b19-ol-0-0-8811],[@b21-ol-0-0-8811]). For benign cases, endoscopic mucosal resection or ESD is the best strategy for tumors \<2 cm in diameter ([@b22-ol-0-0-8811],[@b23-ol-0-0-8811]). Previously, partial colectomy was advised for tumors \>2 cm in diameter ([@b24-ol-0-0-8811]). However, in our experience, lesions measuring 3--5 cm and limited to the submucosa may be completely resected by ESE, without bleeding or perforation. This requires a thorough hemostatic procedure at the edge and bottom of the wound, and excavation should be performed close to the submucosal layer while incising the bottom of the tumor.

At present, perforation is the greatest concern of endoscopists ([@b25-ol-0-0-8811]). The development of endoscopic techniques provides several closure approaches during ESD to deal with perforation, including the following: Clipping; clipping and then strengthening with an endoloop; purse string suture with metallic clips and endoloop; and interrupted suture with endoloop and metallic clip ([@b26-ol-0-0-8811]). The advent of endoscopic closure techniques has expanded the indications for ESD for colonic GCTs located within the submucosal layer, avoiding invasive procedures.

The first malignant GCT was described by Ravich in 1945 ([@b27-ol-0-0-8811]). Notably, this particular clinically malignant tumor may be histologically malignant or benign. The histological features of malignant GCTs have been described previously ([@b3-ol-0-0-8811],[@b11-ol-0-0-8811]). Herein, the clinical features that may indicate a GCT with malignant potential, all of which are high-risk signals that call for clinicians\' special attention are summarized as follows: Advanced patient age, tumor size \>5 cm, rapid recent growth, and an infiltrative growth pattern. It is recommended that patients with suspected GCTs undergo a preoperative examination that includes EUS and abdominal computerized tomography, to determine the possibility of endoscopic treatment. Traditional surgery is indicated for a GCT measuring 5 cm in maximum diameter, an infiltrative growth pattern invading the muscular layer and lympho-vascular invasion, or further metastasis. The role of chemotherapy and radiotherapy remains indefinite, as there are only a few cases of malignant GCTs that responded to chemotherapy ([@b28-ol-0-0-8811],[@b29-ol-0-0-8811]).

In summary, colonic GCTs are rare, primarily occur in the right colon and typically follow a benign course. The initial clinical manifestation and endoscopic appearance is non-specific, and therefore a correct diagnosis is difficult to achieve. The advancement of endoscopic technique has partially replaced partial colectomy for the treatment of benign GCTs. However, traditional surgery remains the optimal strategy for malignant cases.
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![ESD procedure. (A) Submucosal injection of mixed solution around the lesion to lift the tumor. (B) Submucosal dissection of the lesion. (C) Wound appearance. (D) Wound closing using clips. ESD, endoscopic submucosal dissection.](ol-16-02-1419-g00){#f1-ol-0-0-8811}

![ESE procedure. (A) Submucosal injection of mixed solution and mucosectomy. (B) Wound surface. (C) Wound closure with clips. ESE, endoscopic submucosal excavation.](ol-16-02-1419-g01){#f2-ol-0-0-8811}

![Colonoscopy and EUS image of colonic GCTs. (A) Colonoscopic view of a 0.4-cm GCT located in the ascending colon. (B) Colonoscopic view of a 3.0-cm GCT located in the cecum. (C) Homogenous and hypoechoic lesion originating from muscularis mucosa, by EUS. (D) GCT image by EUS, showing granular-type heterogeneous and hypoechoic lesion confined to the submucosal layer. EUS, endoscopic ultrasonography; GCTs, granular cell tumors.](ol-16-02-1419-g02){#f3-ol-0-0-8811}

![Histologic features of colonic granular cell tumor. (A) Hematoxylin and eosin showing ribbons of round-to-polyhedral cells that were characterized by small, uniform nuclei surrounded by abundant granular eosinophilic cytoplasm (original magnification, ×200). (B) Immunohistochemical analysis revealed positive staining of S-100 in the nucleus and cytoplasm (original magnification, ×200).](ol-16-02-1419-g03){#f4-ol-0-0-8811}

###### 

Patient clinical characteristics.

  Patient   Age, years   Sex      Presentation     Tumor location    Invading layer      Tumor size, cm^[a](#tfn1-ol-0-0-8811){ref-type="table-fn"}^   Excision
  --------- ------------ -------- ---------------- ----------------- ------------------- ------------------------------------------------------------- ----------
  1         60           Male     Asymptomatic     Ascending colon   Submucosa           0.6                                                           ESD
  2         67           Female   Asymptomatic     Cecum             Submucosa           0.5                                                           ESD
  3         42           Male     Hematochezia     Ascending colon   Submucosa           3.0                                                           ESE
  4         50           Male     Asymptomatic     Ascending colon   Muscularis mucosa   0.4                                                           ESD
  5         40           Female   Abdominal pain   Cecum             Submucosa           1.2                                                           ESD
  6         52           Male     Asymptomatic     Ascending colon   Muscularis mucosa   0.8                                                           ESD
  7         47           Female   Asymptomatic     Ascending colon   Submucosa           1.5                                                           ESD
  8         45           Male     Abdominal pain   Cecum             Submucosa           1.0                                                           ESD
  9         57           Female   Asymptomatic     Ascending colon   Muscularis mucosa   0.8                                                           ESD
  10        45           Male     Asymptomatic     Ascending colon   Submucosa           1.5                                                           ESD
  11        44           Male     Asymptomatic     Ascending colon   Submucosa           0.8                                                           ESD

Maximum diameter. ESD, endoscopic submucosal dissection; ESE, endoscopic submucosal excavation.
